{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:12:20Z","timestamp":1793383940286,"version":"4.5.0"},"reference-count":36,"publisher":"Society of Nuclear Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,5,8]]},"published-print":{"date-parts":[[2025,8]]},"DOI":"10.2967\/jnumed.125.269914","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T14:00:18Z","timestamp":1749132018000},"page":"1245-1251","source":"Crossref","is-referenced-by-count":17,"title":["Meeting Upcoming Clinical and Diagnostic Needs in Oncologic Imaging: A Structured Reporting System for Fibroblast-Activation-Protein\u2013Targeted Imaging\u2014FAP-RADS Version 1.0"],"prefix":"10.2967","volume":"66","author":[{"given":"Emil","family":"Novruzov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel T.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduards","family":"Mamlins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Ledderose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Klauschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Watabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Gorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik L.","family":"Giesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"2025080106551278000_66.8.1245.1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09909-3"},{"key":"2025080106551278000_66.8.1245.2","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1021\/acs.jmedchem.0c02171","article-title":"Imaging of fibroblast activation protein in cancer xenografts using novel (4-quinolinoyl)-glycyl-2-cyanopyrrolidine-based small molecules","volume":"64","author":"Slania","year":"2021","journal-title":"J Med Chem."},{"key":"2025080106551278000_66.8.1245.3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.210443"},{"key":"2025080106551278000_66.8.1245.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.210435"},{"key":"2025080106551278000_66.8.1245.5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s41181-021-00144-x","article-title":"18F-labeled tracers targeting fibroblast activation protein","volume":"6","author":"Lindner","year":"2021","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2025080106551278000_66.8.1245.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05842-5"},{"key":"2025080106551278000_66.8.1245.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267281"},{"key":"2025080106551278000_66.8.1245.8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.semnuclmed.2024.05.010","article-title":"Radiomolecular theranostics with fibroblast-activation-protein inhibitors and peptides","volume":"54","author":"Baum","year":"2024","journal-title":"Semin Nucl Med."},{"key":"2025080106551278000_66.8.1245.9","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.220749"},{"key":"2025080106551278000_66.8.1245.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266652"},{"key":"2025080106551278000_66.8.1245.11","unstructured":"SOFIE Biosciences. A phase 2, multicenter, single arm, open label, non-randomized study of [18F]FAPI-74 PET in patients with gastrointestinal cancers. ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/study\/NCT05641896. Revised February 12, 2025. Accessed May 21, 2025."},{"key":"2025080106551278000_66.8.1245.12","unstructured":"Deroose C . Multicenter validation trial of [18F]AlF-FAPI-74 for PET imaging of cancer-associated fibroblasts through fibroblast activation protein inhibitors (FAPI) in different tumor types. ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/study\/NCT06782412. Revised February 12, 2025. Accessed May 21, 2025."},{"key":"2025080106551278000_66.8.1245.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.227967"},{"key":"2025080106551278000_66.8.1245.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269002"},{"key":"2025080106551278000_66.8.1245.15","doi-asserted-by":"publisher","DOI":"10.2174\/1874306400903010123"},{"key":"2025080106551278000_66.8.1245.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.215913"},{"key":"2025080106551278000_66.8.1245.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.245084"},{"key":"2025080106551278000_66.8.1245.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264069"},{"key":"2025080106551278000_66.8.1245.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264941"},{"key":"2025080106551278000_66.8.1245.20","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419"},{"key":"2025080106551278000_66.8.1245.21","doi-asserted-by":"crossref","first-page":"9750080","DOI":"10.1155\/2021\/9750080","article-title":"FAPI-04 uptake in healthy tissues of cancer patients in 68Ga-FAPI-04 PET\/CT imaging","volume":"2021","author":"G\u00fcndo\u011fan","year":"2021","journal-title":"Contrast Media Mol Imaging."},{"key":"2025080106551278000_66.8.1245.22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/RLU.0000000000003968","article-title":"Uterine uptake of 68Ga-FAPI-04 in uterine pathology and physiology","volume":"47","author":"Zhang","year":"2022","journal-title":"Clin Nucl Med."},{"key":"2025080106551278000_66.8.1245.23","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1053\/j.semnuclmed.2023.02.001","article-title":"FAPI-avid nonmalignant PET\/CT findings: an expedited systematic review","volume":"53","author":"Bentestuen","year":"2023","journal-title":"Semin Nucl Med."},{"key":"2025080106551278000_66.8.1245.24","doi-asserted-by":"crossref","first-page":"20220994","DOI":"10.1259\/bjr.20220994","article-title":"Benign lesions with 68Ga-FAPI uptake: a retrospective study","volume":"96","author":"Shu","year":"2023","journal-title":"Br J Radiol."},{"key":"2025080106551278000_66.8.1245.25","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s12149-021-01673-w","article-title":"Characterization of the benign lesions with increased 68Ga-FAPI-04 uptake in PET\/CT","volume":"35","author":"Zheng","year":"2021","journal-title":"Ann Nucl Med."},{"key":"2025080106551278000_66.8.1245.26","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00259-021-05472-3","article-title":"Increased uptake of 68Ga-DOTA-FAPI-04 in bones and joints: metastases and beyond","volume":"49","author":"Qin","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025080106551278000_66.8.1245.27","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00259-023-06146-y","article-title":"Diagnostic efficiency of [68Ga]Ga-DOTA-FAPI-04 in differentiating periprosthetic hip joint infection and aseptic failure","volume":"50","author":"Wang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025080106551278000_66.8.1245.28","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1007\/s00259-024-06733-7","article-title":"FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis","volume":"51","author":"Maliha","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025080106551278000_66.8.1245.29","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s00256-023-04335-2","article-title":"Increased 18F-FAPI uptake in bones and joints of lung cancer patients: characteristics and distributions","volume":"52","author":"Liu","year":"2023","journal-title":"Skeletal Radiol."},{"key":"2025080106551278000_66.8.1245.30","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s11307-022-01759-5","article-title":"Distinguishing benign and malignant findings on [68Ga]-FAPI PET\/CT based on quantitative SUV measurements","volume":"25","author":"Dabir","year":"2023","journal-title":"Mol Imaging Biol."},{"key":"2025080106551278000_66.8.1245.31","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jacr.2022.03.012","article-title":"ACR-RADS programs current state and future opportunities: defining a governance structure to enable sustained success","volume":"19","author":"Davenport","year":"2022","journal-title":"J Am Coll Radiol."},{"key":"2025080106551278000_66.8.1245.32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.217653"},{"key":"2025080106551278000_66.8.1245.33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","article-title":"Prostate-specific membrane antigen reporting and data system version 2.0","volume":"84","author":"Werner","year":"2023","journal-title":"Eur Urol."},{"key":"2025080106551278000_66.8.1245.34","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12149-018-1291-7","article-title":"Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications","volume":"32","author":"Werner","year":"2018","journal-title":"Ann Nucl Med."},{"key":"2025080106551278000_66.8.1245.35","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1007\/s10278-024-01104-y","article-title":"An automated deep learning-based framework for uptake segmentation and classification on PSMA PET\/CT imaging of patients with prostate cancer","volume":"37","author":"Li","year":"2024","journal-title":"J Imaging Inform Med."},{"key":"2025080106551278000_66.8.1245.36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13550-022-00948-1","article-title":"Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET","volume":"12","author":"Leung","year":"2022","journal-title":"EJNMMI Res."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.269914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T13:55:59Z","timestamp":1754056559000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.269914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,1]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.2967\/jnumed.125.269914"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.269914","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]}}}